Evommune (EVMN) Profit After Tax (2024 - 2026)

Evommune (EVMN) has 3 years of Profit After Tax data on file, last reported at -$21.7 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 48.89% year-over-year to -$21.7 million in Q1 2026; TTM through Mar 2026 was -$77.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$68.9 million, down 3.09% from the prior year.
• Profit After Tax for Q1 2026 stood at -$21.7 million, up from -$28.3 million in the prior quarter.
• Over the last five years, Profit After Tax for EVMN reached as high as -$12.5 million in Q3 2025 and fell as low as -$28.3 million in Q4 2025.
• Historically, Profit After Tax has averaged -$18.9 million across 3 years, with a median of -$18.3 million in 2024.
• Across the five-year window, Profit After Tax increased 21.62% in 2025 and slumped 48.89% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$20.7 million in 2024, then slumped by 36.41% to -$28.3 million in 2025, then rose by 23.34% to -$21.7 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$21.7 million in Q1 2026, -$28.3 million in Q4 2025, and -$12.5 million in Q3 2025.